Results 1 to 10 of about 170,256 (261)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Frontiers in Pharmacology, 2021
Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients.
Tan Chongqing, Tan Chongqing, Li Sini, Zeng Xiaohui, Peng Liubao, Peng Liubao, Peng Ye, Peng Ye, Qin Shuxia, Qin Shuxia, Wang Liting, Wang Liting, Wu Meiyu, Wu Meiyu, Wan Xiaomin, Wan Xiaomin   +15 more
doaj   +1 more source

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma

IJU Case Reports, 2022
Introduction Before the approval of enfortumab vedotin, no standard treatment was available as the salvage treatment for patients with metastatic urothelial carcinoma who had failed second‐line or later pembrolizumab.
Nobutaka Nishimura, Makito Miyake, Takuto Shimizu, Akira Tachibana, Nobumichi Tanaka, Kiyohide Fujimoto   +5 more
doaj   +1 more source

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Frontiers in Pharmacology, 2021
Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC).Methods: We found 12 phase II or III ...
Weidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huang   +3 more
doaj   +1 more source

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma

Current Oncology, 2022
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease.
Laurys Boudin, Jean-Baptiste Morvan, Juliette Thariat, Denis Métivier, Pierre-Yves Marcy, David Delarbre   +5 more
doaj   +1 more source

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

eLife, 2021
Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development.
Teresa WM Fan, Richard M Higashi, Huan Song, Saeed Daneshmandi, Angela L Mahan, Matthew S Purdom, Therese J Bocklage, Thomas A Pittman, Daheng He, Chi Wang, Andrew N Lane   +10 more
doaj   +1 more source

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

Thoracic Cancer, 2022
Background A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐
Hyung Jun Park, Yong Man Kim, Jae Seob Jung, Wonjun Ji, Jae Cheol Lee, Chang‐Min Choi   +5 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2021
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC).
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo   +13 more
doaj   +1 more source

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study

Cancer Medicine, 2023
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established.
Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi   +15 more
doaj   +1 more source

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Journal for ImmunoTherapy of Cancer, 2019
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%.
Zuan Lin
doaj   +1 more source

A Case of Stevens-Johnson Syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab

Current Problems in Cancer: Case Reports, 2021
Chemo-immunotherapy consisting of pemetrexed and pembrolizumab is first line therapy for individuals with non-squamous non-small cell lung cancer without ALK or EGFR mutations.
Michael H. Storandt, Rishi Seth
doaj   +1 more source